Intravenous (IV) and subcutaneous (SC) tocilizumab (RoActemra®), an IL-6 receptor
antagonist, are approved (±methotrexate) in numerous countries throughout the world, for …

Rheumatoid arthritis (RA) is a chronic systemic autoimmune disease that primarily targets
synovial joints, resulting in pain and functional limitations. It is the most common …

Rheumatoid arthritis is an autoimmune disease that primarily affects the joints. The
emergence of highly effective anti-rheumatic drugs such as biologic agents and janus …

Recent therapeutic advances in juvenile idiopathic arthritis (JIA) have made remission an
achievable goal for most patients. Reaching this target leads to improved outcomes. The …

Objectives To provide an update of the European League Against Rheumatism (EULAR)
rheumatoid arthritis (RA) management recommendations to account for the most recent …

With novel therapies in development, there is an opportunity to consider asthma remission
as a treatment goal. In this Rostrum, we present a generalized framework for clinical and …

Heat shock proteins (HSPs) play cytoprotective activities under pathological conditions
through the initiation of protein folding, repair, refolding of misfolded peptides, and possible …

Background Baricitinib is an oral, reversible, selective Janus kinase 1 and 2 inhibitor.
Methods In this phase III, double-blind 24-week study, 684 biologic disease-modifying …

Rheumatoid arthritis (RA) is a systemic autoimmune disease characterized by chronic
inflammation of the joints. Untreated RA leads to a destruction of joints through the erosion …

Objectives To provide an update of the EULAR rheumatoid arthritis (RA) management
recommendations addressing the most recent developments in the field. Methods An …